You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Oxford-AstraZeneca Covid-19 vaccine shows immune response in older adults

The vaccine causes few side effects and provokes a response in T-cells that target the virus within 14 days of the first dose and a protective antibody response within 28 days of the booster dose

Topics
Coronavirus Vaccine | AstraZeneca | Oxford University

James Paton & Suzi Ring | Bloomberg 

Coronavirus, vaccine, tests, covid, drugs, clinical trials
The results of Oxford’s phase 2 study show that the vaccine is better tolerated in older people and produces a similar immune response in old and young adults

The University of Oxford confirmed that the Covid-19 vaccine it’s developing with produced strong immune responses in older adults in an early study, with key findings from the last phase of tests expected in the coming weeks.

The results, published Thursday in The Lancet medical journal, shed more light on preliminary data released in recent months showing the experimental shot generated an immune response in the elderly, who are at highest risk of severe illness.

“This is a very important step, because the big worry with any vaccine is that it doesn’t work so well in older people,” Richard Horton.

The Lancet’s editor-in-chief, said in an interview with Bloomberg Television. The data is “another brick in the house that we’re trying to build for this vaccine”.

Researchers still await late-stage trial results that will show whether the vaccine can meet the high bar set by front-runners Pfizer and Moderna The Astra-Oxford data readout will come after there have been 53 confirmed cases of Covid-19 in the trial, Andrew Pollard, Oxford’s chief trial investigator said.

Pollard also said Astra and Oxford will release the “high-level” results of the trials once they pass the infection benchmark immediately, followed by a more detailed, peer-reviewed data analysis in a scientific journal weeks later. shares were little changed in London trading after rising as much as 1.7 per cent earlier Thursday.

The past two weeks have brought a flurry of promising vaccine news. Pfizer, working with Germany’s BioNTech, said Wednesday that its shot was 95 per cent effective in a final analysis of trial data, paving the way for the company to apply for US regulatory clearance.

Moderna’s vaccine candidate appears equally effective. The results of Oxford’s phase 2 study show that the vaccine is better tolerated in older people and produces a similar immune response in old and young adults.

The study involved 560 adults, including 240 over the age of 70. Older patients have been hardest hit by the pandemic, with the vast majority of deaths occurring in those over 60. Data released in July showed the vaccine generated robust immune responses in adults aged 18 to 55.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 19 2020. 13:27 IST
RECOMMENDED FOR YOU